LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)
NCT03593395 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 291
Last updated 2024-09-03
Summary
This multi-center study will compare the effectiveness of adding virtual peer mentoring (PM) to a structured education-based (STE) transition program for emerging adults with sickle cell disease to determine its effect on decreasing the number of acute care visits per year, improving patient-reported outcomes, and reducing healthcare utilization among emerging adults with sickle cell disease (EA-SCD)
Conditions
Interventions
- OTHER
-
Peer Mentoring [PM]
Virtual Peer Mentoring
- OTHER
-
Structured Education Based Transition Program STE
Education-based program
Sponsors & Collaborators
-
Patient-Centered Outcomes Research Institute
collaborator OTHER -
Atrium Health Levine Cancer Institute
collaborator OTHER -
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Payal Desai, MD · Wake Forest University Health Sciences
-
Raymona Lawrence, DRPH · Wake Forest University Health Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-10
- Primary Completion
- 2023-02-28
- Completion
- 2023-02-28
Countries
- United States
Study Locations
More Related Trials
-
Single Incision Versus Standard Laparoscopic Splenectomy
NCT01276561 ·Status: WITHDRAWN ·Phase: NA
-
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03952039 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04557735 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
NCT05175105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Avatrombopag for Chemotherapy-induced Thrombocytopenia
NCT05218226 ·Status: RECRUITING ·Phase: PHASE2
-
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
NCT07003269 ·Status: ENROLLING_BY_INVITATION
-
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03755518 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia
NCT05350956 ·Status: UNKNOWN ·Phase: PHASE2
-
French Adult Primary Immune Thrombocytopenia
NCT03429660 ·Status: UNKNOWN
-
Pediatric Disease Registry in Essential Thrombocythaemia (ET)
NCT01198717 ·Status: COMPLETED
-
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
NCT07347990 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective,Open-label, Single-arm Study.
NCT05392647 ·Status: UNKNOWN ·Phase: PHASE2
-
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
NCT04797182 ·Status: UNKNOWN ·Phase: PHASE2
-
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
NCT01566695 ·Status: COMPLETED ·Phase: PHASE3
-
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
NCT03469661 ·Status: COMPLETED
-
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
NCT05389007 ·Status: UNKNOWN
-
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
NCT05148299 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)
NCT03964792 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia
NCT04896528 ·Status: UNKNOWN ·Phase: PHASE2
-
Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT03515096 ·Status: COMPLETED ·Phase: PHASE3
-
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
NCT04543591 ·Status: COMPLETED ·Phase: PHASE3
-
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
NCT04516967 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
NCT01972529 ·Status: COMPLETED ·Phase: PHASE3